Jan 23, 2024 7:03am EST Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
Dec 18, 2023 7:03am EST Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
Nov 29, 2023 7:03am EST Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023
Nov 14, 2023 4:15pm EST Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
Oct 23, 2023 7:03am EDT Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
Sep 06, 2023 7:03am EDT Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
Aug 14, 2023 5:36pm EDT Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
Jul 20, 2023 7:03am EDT Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
Jul 18, 2023 7:03am EDT Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
